Document is current
Any future updates will be listed below
-
Authors
Morales, Mónica Guillot https://orcid.org/0000-0001-7509-146X
Montes, Ana Fernández
Fernández-Plana, Julen
Cañete, Ismael Ghanem
Raga, Mireia Gil
Jiménez-Castro, Jerónimo
Martel, Ignacio Juez
Santasusana, Joan Maurel
Marqués, Eduardo Polo
Gómez-España, Ma Auxiliadora
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica
- License Information
-
More Information
Article History
Received: 21 November 2025
Accepted: 24 November 2025
First Online: 7 February 2026
Declarations
:
: Mónica Guillot Morales: reports speaker fee from Merck, MSD, and Servier; advisory board fee from Roche , and GlaxoSmithKline S.A. Ismael Ghanem Cañete: reports speaker fee from Merck, Amgen, and MSD and advisory board–speaker fee from Servier and AstraZeneca. Jerónimo Jiménez-Castro: reports Speaker from Servier, Merck and Amgen. Joan Maurel Santasusana: reports personal fees from Advance Medical, Amgen, Cancer Expert Now and MSD; advisory board fee from Delcath Systems Inc, GlaxoSmithKline SA (GSK), and Incyte Biosciences International; grant from Amgen, Guardant, Incyte, Merck, and Terumo and non-financial support from GEMCAD. Ana Fernández Montes, Julen Fernández-Plana, Mª Auxiliadora Gómez-España, Mireia Gil Raga, Ignacio Juez Martel, and Eduardo Polo Marqués have nothing to disclose.
: Not applicable. The manuscript does not contain clinical studies or patient data.
